Pavlos Msaouel

Generating author description...

All published works

Action	Title	Year	Authors
+	Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials	2025	Alexander D. Sherry Yufei Liu Pavlos Msaouel Timothy A. Lin Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam
+	Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials	2025	Avital M. Miller Adina H. Passy Alexander D. Sherry Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Gabrielle S. Kupferman Esther J. Beck Pavlos Msaouel Ethan B. Ludmir
+	Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study	2024	T. Kleber Alexander D. Sherry Andrew Arifin Gabrielle S. Kupferman Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Esther J. Beck Avital M Miller Adina H. Passy
+	Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting	2024	Stephanie Berg Salvatore La Rosa Tian Zhang Phillip M. Pierorazio Laurence Albigès Kathryn E. Beckermann Matthew T. Campbell Maria I. Carlo Katie Coleman Daniel J. George
+	Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Zachary R. McCaw Ethan B. Ludmir Erik W. van Zwet
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses	2024	Alexander D. Sherry Adina H. Passy Zachary R. McCaw Joseph Abi Jaoude Timothy A. Lin Ramez Kouzy Avital M. Miller Gabrielle S. Kupferman Esther J. Beck Pavlos Msaouel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Data from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Data from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase <scp>III</scp> oncology trials	2024	Alexander D. Sherry Timothy A. Lin Zachary R. McCaw Esther J. Beck Ramez Kouzy Joseph Abi Jaoude Adina H. Passy Avital M. Miller Gabrielle S. Kupferman Clifton D. Fuller
+ PDF Chat	Secondary endpoint utilization and publication rate among phase III oncology trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Molly B. El-Alam Roshal R. Patel Alex Koong Christine Lin
+	Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials	2024	Alexander D. Sherry Pavlos Msaouel Avital M. Miller Timothy A. Lin Gabrielle S. Kupferman Joseph Abi Jaoude Ramez Kouzy Molly B. El-Alam Roshal R. Patel Alex Koong
+ PDF Chat	Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials	2024	Alexander D. Sherry Pavlos Msaouel Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Cullen M. Taniguchi Clifton D. Fuller Bruce D. Minsky Ethan B. Ludmir
+ PDF Chat	Decoding Randomized Controlled Trials: An Information Science Perspective	2024	Pavlos Msaouel
+ PDF Chat	An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Zachary R. McCaw Ethan B. Ludmir Erik W. van Zwet
+ PDF Chat	Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials	2024	Alexander D. Sherry Pavlos Msaouel Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Esther J. Beck Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Eugene J. Koay
+ PDF Chat	Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020	2024	Alexander D. Sherry Andrew W. Hahn Zachary R. McCaw Joseph Abi Jaoude Ramez Kouzy Timothy A. Lin Bruce D. Minsky Clifton D. Fuller Tomer Meirson Pavlos Msaouel
+	Association of differential censoring with survival and suboptimal control arms among oncology clinical trials	2024	Eric J. Hsu Timothy A. Lin Dor Reuven Dabush Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam
+ PDF Chat	Risk–benefit trade-offs and precision utilities in phase I-II clinical trials	2023	Pavlos Msaouel Juhee Lee Peter F. Thall
+ PDF Chat	Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy	2023	Alexander D. Sherry Pavlos Msaouel Zachary R. McCaw Joseph Abi Jaoude Eric J. Hsu Ramez Kouzy Roshal R. Patel Yumeng Yang Timothy A. Lin Cullen M. Taniguchi
+ PDF Chat	Interpreting Randomized Controlled Trials	2023	Pavlos Msaouel Juhee Lee Peter F. Thall
+	Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes	2023	Peter F. Thall Yong Zang Andrew G. Chapple Ying Yuan Ruitao Lin David Marín Pavlos Msaouel
+	Interpreting Randomized Controlled Trials	2023	Pavlos Msaouel Juhee Lee Peter F. Thall
+	Risk Model Development and Validation in Clinical Oncology: Lessons Learned	2022	Gary H. Lyman Pavlos Msaouel Nicole M. Kuderer
+	Utility-Based Bayesian Personalized Treatment Selection for Advanced Breast Cancer	2022	Juhee Lee Peter F. Thall Bora Lim Pavlos Msaouel
+	Bayesian Treatment Screening and Selection Using Subgroup-Specific Utilities of Response and Toxicity	2022	Juhee Lee Peter F. Thall Pavlos Msaouel
+ PDF Chat	A Causal Framework for Making Individualized Treatment Decisions in Oncology	2022	Pavlos Msaouel Juhee Lee José A. Karam Peter F. Thall
+ PDF Chat	The Big Data Paradox in Clinical Practice	2022	Pavlos Msaouel
+ PDF Chat	Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive	2022	Andrew W. Hahn Nazlı Dizman Pavlos Msaouel
+ PDF Chat	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit	2021	Vicente Valentí Paula Jiménez‐Fonseca Pavlos Msaouel Ramón Salazar Alberto Carmona‐Bayonas
+ PDF Chat	Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials	2021	Pavlos Msaouel
+ PDF Chat	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes	2021	Pavlos Msaouel Juhee Lee Peter F. Thall
+	Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries	2021	Alberto Carmona‐Bayonas Paula Jiménez‐Fonseca Javier Gállego Pavlos Msaouel
+ PDF Chat	Causal Diagram Techniques for Urologic Oncology Research	2020	Daniel D. Shapiro Pavlos Msaouel
+	Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs).	2020	Pavlos Msaouel Michael L. Van Alstine Clara Oromendia Jianjun Gao Yinghong Wang Bilal A. Siddiqui Arlene O. Siefker‐Radtke Amishi Y. Shah Leah Shaw Lidia López
+	Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).	2020	Andrew W. Hahn Omar Alhalabi Funda Meric‐Bernstam Aung Naing Eric Jonasch Pavlos Msaouel Sarina A. Piha‐Paul David S. Hong Shubham Pant Timothy A. Yap
+	A phase I‐II design based on periodic and continuous monitoring of disease status and the times to toxicity and death	2020	Juhee Lee Peter F. Thall Pavlos Msaouel
+ PDF Chat	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials	2020	Andrew W. Hahn Omar Alhalabi Pavlos Msaouel Funda Meric‐Bernstam Aung Naing Eric Jonasch Sarina A. Piha‐Paul David S. Hong Shubham Pant Timothy A. Yap
+	Assessment of cognitive biases and biostatistics knowledge of medical residents: a multicenter, cross-sectional questionnaire study	2014	Pavlos Msaouel Theocharis Kappos Athanasios Tasoulis Alexandros P. Apostolopoulos Ioannis Lekkas Elli-Sophia Tripodaki N. Keramaris
+ PDF Chat	Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia	2013	Anthony Lam Krishna Gundabolu Ashwin Sridharan Rishi Jain Pavlos Msaouel Grigorios Chrysofakis Yiting Yu Ellen Friedman Elizabeth Price Stanley L. Schrier

Common Coauthors

Coauthor	Papers Together
Timothy A. Lin	55
Alexander D. Sherry	55
Joseph Abi Jaoude	55
Ethan B. Ludmir	55
Ramez Kouzy	55
Gabrielle S. Kupferman	50
Adina H. Passy	47
Esther J. Beck	47
Avital M. Miller	47
Roshal R. Patel	46
Chad Tang	44
Bruce D. Minsky	44
Charles R. Thomas	42
Christine M. Parseghian	41
Fumiko Chino	41
Marcus A. Florez	41
Victoria Serpas Higbie	41
Michael J. Overman	41
Zachary R. McCaw	12
Peter F. Thall	10
Juhee Lee	8
Clifton D. Fuller	7
Tomer Meirson	6
Andrew W. Hahn	4
Nizar M. Tannir	4
Alex Koong	4
Aung Naing	2
Jason Roszik	2
Cullen M. Taniguchi	2
Shubham Pant	2
Charles R. Thomas	2
Hung Le	2
Yumeng Yang	2
Christine Lin	2
Eric J. Hsu	2
Erik W. van Zwet	2
Timothy A. Yap	2
Christine Lin	2
Paula Jiménez‐Fonseca	2
Sarina A. Piha‐Paul	2
Eric Jonasch	2
Ryan Sun	2
Eugene J. Koay	2
David S. Hong	2
Alberto Carmona‐Bayonas	2
Molly B. El Alam	2
Vivek Subbiah	2
Omar Alhalabi	2
Funda Meric‐Bernstam	2
Erick Campbell	2

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes	2021	Pavlos Msaouel Juhee Lee Peter F. Thall	17
+ PDF Chat	Causal Diagram Techniques for Urologic Oncology Research	2020	Daniel D. Shapiro Pavlos Msaouel	12
+ PDF Chat	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations	2016	Sander Greenland Stephen Senn Kenneth J. Rothman John B. Carlin Charles Poole Steven N. Goodman Douglas G. Altman	12
+ PDF Chat	Interpreting Randomized Controlled Trials	2023	Pavlos Msaouel Juhee Lee Peter F. Thall	11
+ PDF Chat	A Causal Framework for Making Individualized Treatment Decisions in Oncology	2022	Pavlos Msaouel Juhee Lee José A. Karam Peter F. Thall	11
+	Seven myths of randomisation in clinical trials	2012	Stephen Senn	9
+ PDF Chat	Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials	2023	Timothy A. Lin Alexander D. Sherry Ethan B. Ludmir	8
+ PDF Chat	Robust causal inference using directed acyclic graphs: the R package ‘dagitty’	2016	Johannes Textor Benito van der Zander Mark S. Gilthorpe Maciej Liśkiewicz George T. H. Ellison	8
+ PDF Chat	Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive	2022	Andrew W. Hahn Nazlı Dizman Pavlos Msaouel	8
+ PDF Chat	The Big Data Paradox in Clinical Practice	2022	Pavlos Msaouel	7
+ PDF Chat	Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs	2023	Christopher M. Booth Elizabeth A. Eisenhauer Bishal Gyawali Ian F. Tannock	7
+	Causal Diagrams for Epidemiologic Research	1999	Sander Greenland Judea Pearl James M. Robins	6
+	Regression Modeling Strategies	2015	Frank E. Harrell	6
+	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement	2019	David M. Kent Jessica K. Paulus David van Klaveren Ralph B. D’Agostino Steven N. Goodman Rodney A. Hayward John P. A. Ioannidis Bray Patrick‐Lake Sally C. Morton Michael Pencina	6
+	Statistical Issues in Drug Development	2021	Stephen Senn	6
+ PDF Chat	Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials	2021	Pavlos Msaouel	6
+ PDF Chat	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves	2012	Patricia Guyot A. E. Ades Mario JNM Ouwens Nicky J. Welton	5
+ PDF Chat	Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times	2015	Yanxun Xu Peter Müller Abdus S. Wahed Peter F. Thall	5
+ PDF Chat	Causal inference and the data-fusion problem	2016	Elias Bareinboim Judea Pearl	5
+	Utility-Based Bayesian Personalized Treatment Selection for Advanced Breast Cancer	2022	Juhee Lee Peter F. Thall Bora Lim Pavlos Msaouel	5
+ PDF Chat	The statistical properties of RCTs and a proposal for shrinkage	2021	Erik W. van Zwet Simon Schwab Stephen Senn	5
+	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials	2020	Dario Pasalic Gwendolyn J. McGinnis Clifton D. Fuller Aaron J. Grossberg Vivek Verma W. Ian P. Mainwaring Austin B. Miller Timothy A. Lin Amit Jethanandani Andres F. Espinoza	5
+ PDF Chat	Mastering variation: variance components and personalised medicine	2015	Stephen Senn	5
+ PDF Chat	There Is Individualized Treatment. Why Not Individualized Inference?	2016	Keli Liu Xiao‐Li Meng	5
+	Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects	2018	David M. Kent Ewout W. Steyerberg David van Klaveren	5
+ PDF Chat	Confounding and Collapsibility in Causal Inference	1999	Sander Greenland Judea Pearl James M. Robins	5
+ PDF Chat	The ASA Statement on <i>p</i>-Values: Context, Process, and Purpose	2016	Ronald L. Wasserstein Nicole A. Lazar	5
+ PDF Chat	Prognosis vs Treatment Interaction	2018	Jack Cuzick	4
+	Bayesian Designs for Phase I–II Clinical Trials	2017	Ying Yuan Hoang Q. Nguyen Peter F. Thall	4
+ PDF Chat	Bayesian nonparametric statistics: A new toolkit for discovery in cancer research	2017	Peter F. Thall Peter Müeller Yanxun Xu Michele Guindani	4
+	FDA validation of surrogate endpoints in oncology: 2005–2022	2022	Anushka Walia Alyson Haslam Vinay Prasad	4
+	Addressing Exaggeration of Effects from Single RCTs	2021	Erik W. van Zwet Simon Schwab Sander Greenland	4
+	Air Pollution and Hospital Admissions for Heart Disease in Eight U.S. Counties	1999	Sander Greenland J. Pearl James M. Robins	4
+	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies	2021	Zachary R. McCaw Lü Tian Jiawei Wei Brian Claggett Frank Bretz Garrett M. Fitzmaurice L. J. Wei	4
+ PDF Chat	Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer	2012	Lu Wang Andrea Rotnitzky Xihong Lin Randall E. Millikan Peter F. Thall	4
+ PDF Chat	Forest plots and the interpretation of subgroups	2005	Jack Cuzick	4
+	Controversies concerning randomization and additivity in clinical trials	2004	Stephen Senn	4
+ PDF Chat	Semantic and cognitive tools to aid statistical science: replace confidence and significance by compatibility and surprise	2020	Zad Rafi Sander Greenland	4
+ PDF Chat	Statistical Remedies for Medical Researchers	2019	Peter F. Thall	4
+	The Abuse of Power	2001	John M. Hoenig Dennis M. Heisey	4
+	How to Use a Subgroup Analysis	2014	Xin Sun John P. A. Ioannidis Thomas Agoritsas Ana Carolina Alba Gordon Guyatt	4
+	Why Most Discovered True Associations Are Inflated	2008	John P. A. Ioannidis	4
+	Extending inferences from a randomized trial to a target population	2019	Issa J Dahabreh Miguel A. Hernán	4
+	Bayesian Treatment Screening and Selection Using Subgroup-Specific Utilities of Response and Toxicity	2022	Juhee Lee Peter F. Thall Pavlos Msaouel	4
+ PDF Chat	Optimizing Natural Killer Cell Doses for Heterogeneous Cancer Patients on the Basis of Multiple Event Times	2018	Juhee Lee Peter F. Thall Katy Rezvani	3
+ PDF Chat	Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany	2017	Georg Isbary Thomas Staab Volker Eric Amelung Charalabos‐Markos Dintsios Christof Iking‐Konert Sonja Mariotti Nesurini Miriam Walter Jörg Ruof	3
+ PDF Chat	Fisher, Bradford Hill, and randomization	2003	P. Armitage	3
+ PDF Chat	Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding	2017	Fangrong Yan Peter F. Thall K.H. Lu Mark R. Gilbert Ying Yuan	3
+ PDF Chat	‘Optimism bias’ in contemporary national clinical trial network phase III trials: are we improving?	2018	Kaveh Zakeri Sonal S. Noticewala Lucas K. Vitzthum E. Sojourner Hanjie Shen Loren K. Mell	3
+	Bayesian statistics in oncology	2009	Michel Adamina George Tomlinson Ulrich Güller	3